Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding.
Deng W, Li H, Zhang Y, Lin Y, Chen C, Chen J, Huang Y, Zhou Y, Tang Y, Ding J, Yuan K, Xu L, Li Y, Zhang S.
Deng W, et al. Among authors: li y, li h.
Biochem Pharmacol. 2023 Apr;210:115463. doi: 10.1016/j.bcp.2023.115463. Epub 2023 Feb 26.
Biochem Pharmacol. 2023.
PMID: 36849060